NightHawk Biosciences Long Term Debt

The latest long-term debt for NHWK is $5.5T as of September 2025. That compares with $11T in the prior-year period — down 51.8% year over year. Investors often review this figure alongside NightHawk Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, NHWK's long-term debt moved from $11T to $5.5T — a 51.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in NightHawk Biosciences's operating scale or balance-sheet position.

A long-term debt figure of $5.5T for NHWK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NHWK's long-term debt ($5.5T), review year-over-year change from $11T, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack NightHawk Biosciences's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.